- Yield Growth (CSE:BOSS) has begun research into plant-based topical products that could fight or prevent infectious diseases
- The research will include a study examining the antimicrobial effects of natural compounds
- Company subsidiary, Urban Juve, will soon launch a line of hand care products, including hand sanitiser
- Yield Growth (BOSS) is up 23.08 per cent to $0.16 per share
Cannabis company, Yield Growth (CSE:BOSS), has begun research into plant-based topical products to fight or prevent infectious diseases.
The company’s research will include a study examining natural compounds and their antimicrobial, antiviral properties.
Yield Growth already has experience in producing plant-based skincare products, such as its THC-infused topical gels, balms, and body oils. The company now hopes it can apply its existing intellectual property to the growing demand for antiviral therapies.
If the research and development program shows promising results, Yield Growth will move to develop natural compounds into antiviral treatments.
Yield Growth CEO, Penny White, mentioned the impact that the COVID-19 outbreak has had on the company’s new direction.
“While we continue to market, develop, and launch products through our existing brands, we are leveraging our experienced team to conduct research and develop products that can help fight against COVID-19 and other infectious diseases,” she said.
Yield Growth’s research and development program is likely to benefit from the actions of the company’s subsidiaries. One subsidiary, Urban Juve, will soon launch a line of hand care products, including hand sanitiser.
Another, Flourish Mushroom Labs, recently bought an interest in Translational Life Sciences. The pharmaceutical and contract research organisation is currently conducting research into restricted substances for therapeutic use.
According to Yield Growth’s Director of Product Research, Bhavna Solecki, herbs and essential oils have been used for centuries for their antiviral, antifungal and antibacterial properties.
“Essential oils and other plant-based ingredients may be a potential alternative to synthetic compounds, because of the resistance that pathogenic microorganisms have developed.
With the rapid spread of COVID-19, our research and development team is working to provide natural solutions based on ancient plant pharmacology,” she said.
Yield Growth (BOSS) is up 23.08 per cent to $0.16 per share as of 2:43pm EST.